Previous 10 | Next 10 |
AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company’s Board of Directors for personal reasons, effective March 7, 2024. “AbCellera continues to expand the frontier of biotech, a nefariously difficult an...
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time) KeyBanc Capital Markets Life Science...
2024-02-22 14:41:34 ET More on Amgen, Eli Lilly, etc. Pfizer's Post-Pandemic Pivot Pfizer: Turnaround Is Gaining Momentum Eli Lilly: Yes, It Is Too Late To Join The Party Novo to face Wegovy competition in India as local versions loom: Reuters Weight-...
2024-02-20 23:45:21 ET AbCellera Biologics Inc. (ABCL) Q4 2023 Results Conference Call February 20, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, CEO Andrew Booth - CFO Conference Call Part...
2024-02-20 23:00:16 ET Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL) Q4 2023 Earnings Call Feb 20, 2024 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics (ABCL) Q4 2023 Earnings Call Tran...
2024-02-20 16:11:18 ET More on AbCellera Biologics AbCellera Biologics: Continuing To Expand Partnerships AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform Abs...
Total revenue of $38 million, compared to $485 million in FY 2022 Total cumulative partner-initiated program starts with downstreams of 87, with 12 new starts in the year Net loss of $0.51 per share on a basic and diluted basis, compared to earnings of $0.56 (basic) and $0.50 (dil...
Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...
2024-02-19 17:35:09 ET Major earnings expected after the bell on Tuesday include: Realty Income Corporation ( O ) Teladoc Health ( TDOC ) Palo Alto Networks ( PANW ) Chesapeake Energy Corporation ( CHK ) SolarEdge Technologies ( SEDG ) Read ...
2024-02-16 17:20:10 ET More on AbCellera Biologics AbCellera Biologics: Continuing To Expand Partnerships AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform Abs...
News, Short Squeeze, Breakout and More Instantly...
AbCellera Biologics Inc. Company Name:
ABCL Stock Symbol:
NASDAQ Market:
AbCellera (Nasdaq: ABCL), Viking Global Investors (“Viking”), and ArrowMark Partners (“ArrowMark”) announced today that they have entered into a collaboration to advance new antibody drug programs with an aim to launch multiple asset-based companies. The firs...
Data show how AbCellera is expanding the reach of T-cell engagers with: CD3-binding antibodies that consistently generate T-cell engagers with potent tumor-cell killing and low cytokine release across multiple tumor targets, including PSMA, B7-H4, and 5T4 Costimulatory CD28-bind...
AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that ...